Skip to main content
Home/Blog/Healthcare PE

Outcome-Based Pricing for Healthcare AI: Why Samara Charges for EBITDA, Not Seats

Written by - Samara Strategy TeamLast Updated - September 24, 2026

Most healthcare AI is priced like software: per seat, per agent. Samara is priced on outcomes. We charge $50K per location per year, and our bar is $50K+ of added EBITDA per location after our fee. Here's the math for multi-site DSOs and MSOs.

Follow Samara on Google

Set Samara as a preferred source and our research shows up more often in your Google Search results, Top Stories, and AI Overviews.

Make Samara a preferred source

Key Insight

Samara's bar for every location: $50K+ of added EBITDA per year after its $50K fee. At a 6x exit multiple, that is $300K of enterprise value created per location, or $1.2M across a 4-location group.

Most Healthcare AI Is Priced Like Software

Look at how most healthcare AI vendors charge and you will see the same models: per seat, per agent, per user, per module. Those models are borrowed from SaaS. They measure how much software you use, not what that software does for your business.

For a multi-site DSO or MSO, that is the wrong unit of value. A private equity sponsor does not underwrite a platform on how many AI agents it licenses. It underwrites EBITDA, margin, and the multiple it can realize at exit. Seat-based pricing leaves the operator to carry all the risk of whether the tool actually moves those numbers.

Samara takes a different approach. Samara is priced on outcomes.

The 3 Outcomes Samara Is Built to Drive

Samara is purpose-built to drive three kinds of customer outcomes. Each one feeds the next: a better patient experience drives operational performance, and operational performance drives business value.

1. Business Outcomes

  • EBITDA expansion at the location and platform level
  • Margin expansion from higher revenue per location on the same fixed cost base
  • OpEx compression by taking repetitive front-office work off staff
  • ROIC protection on every acquisition, so newly added locations earn their purchase price
  • Stronger exit multiples from standardized, measurable, scalable operations

2. Operational Outcomes

  • Higher appointment fill rates across every provider and chair
  • Fewer no-shows through proactive confirmation and smart rebooking
  • Stronger Google and ChatGPT visibility, so new patients find each location in search and in AI answer engines
  • Better reviews that compound into more new-patient demand

3. Patient Outcomes

  • Higher NPS across the patient journey
  • One-touch scheduling, so booking takes seconds rather than a phone tag cycle
  • Easier appointment coordination for reminders, reschedules, and follow-ups

What We Charge, and What We Are Accountable For

Samara's pricing is simple: $50K per location, per year.

Our bar is equally simple: $50K+ of added EBITDA per location, after our fee. In other words, each location should generate at least $100K of incremental EBITDA before Samara's cost, so the net gain to the business is at least $50K per location.

The Enterprise Value Math

For a PE-backed platform, EBITDA is only half the story. Every incremental dollar of EBITDA is capitalized at exit.

At a 6x exit multiple, $50K of added EBITDA per location equals $300K of enterprise value created per location.

Here is how that scales across a portfolio:

LocationsAdded EBITDA (after fee)Enterprise Value at 6x
1$50K$300K
4$200K$1.2M
10$500K$3.0M
25$1.25M$7.5M

A 4-location group adds $200K of EBITDA and $1.2M of enterprise value. That is what Samara is accountable for.

Not Features. Outcomes.

Feature lists are easy to compare and hard to cash. A platform can ship an AI receptionist, an AI scheduler, and a reputation tool and still leave a location's P&L unchanged. Outcome-based pricing forces a different conversation: which locations are underperforming, why, and what it will take to close the gap.

That is how Samara works with DSOs and MSOs. We start with location-level performance, identify what is holding each location back, and deploy the AI workforce against those specific constraints: unfilled schedule capacity, no-shows, weak search and AI visibility, thin review volume, or front-office cost. For more on how this plays out across a portfolio, see our guide to how private equity uses AI to expand EBITDA in healthcare portfolios.

A Question for Multi-Site DSO and MSO Operators

If you run a multi-site DSO or MSO, ask yourself two questions:

  • Do you know what each location is worth today?
  • Do you know what is holding the weakest one back?

If the answer to either is "not exactly," that is where Samara starts. Book a demo to see a location-by-location view of where the EBITDA is, or explore our private equity and DSO pages.

FAQs: Outcome-Based Pricing for Healthcare AI

What is outcome-based pricing in healthcare AI?

Outcome-based pricing ties what a vendor charges to the business results it delivers, rather than to seats, users, or agents. Samara charges $50K per location per year and holds itself to a bar of $50K+ of added EBITDA per location after that fee.

How much does Samara cost per location?

Samara costs $50K per location, per year, for multi-site DSOs and MSOs.

How does added EBITDA translate into enterprise value?

Enterprise value is typically calculated as EBITDA multiplied by an exit multiple. At 6x, every $50K of added EBITDA creates $300K of enterprise value. Across 4 locations, $200K of added EBITDA creates $1.2M of enterprise value.

Who is outcome-based pricing designed for?

It is designed for multi-site DSOs, MSOs, and PE-backed outpatient platforms that measure success in EBITDA, margin, and exit multiples rather than software usage.

Healthcare PEHealthcare AIWorkflow Automation

Ready to transform your practice operations?

Join 500+ healthcare leaders deploying specialized AI workforces to drive EBITDA growth.

See a live demo of the Samara AI platform in under 15 minutes.

Not ready for a demo? See your estimated savings